EP2970236B1 - Pyridin-4-yl derivatives - Google Patents

Pyridin-4-yl derivatives Download PDF

Info

Publication number
EP2970236B1
EP2970236B1 EP14715427.2A EP14715427A EP2970236B1 EP 2970236 B1 EP2970236 B1 EP 2970236B1 EP 14715427 A EP14715427 A EP 14715427A EP 2970236 B1 EP2970236 B1 EP 2970236B1
Authority
EP
European Patent Office
Prior art keywords
ethyl
hydroxypropyl
oxadiazol
hydroxyacetamide
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP14715427.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2970236A1 (en
Inventor
Martin Bolli
Cyrille Lescop
Oliver Nayler
Beat Steiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Priority to NO14715427A priority Critical patent/NO2970236T3/no
Priority to SI201430428T priority patent/SI2970236T1/sl
Priority to PL14715427T priority patent/PL2970236T3/pl
Priority to EP14715427.2A priority patent/EP2970236B1/en
Publication of EP2970236A1 publication Critical patent/EP2970236A1/en
Application granted granted Critical
Publication of EP2970236B1 publication Critical patent/EP2970236B1/en
Priority to HRP20171763TT priority patent/HRP20171763T1/hr
Priority to CY20171101239T priority patent/CY1119619T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Definitions

  • the present invention relates to S1P 1 /EDG1 receptor agonists of Formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions.
  • the invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing a compound of the Formula (I), and their use as compounds improving vascular function and as immunomodulating agents, either alone or in combination with other active compounds or therapies.
  • the human immune system is designed to defend the body against foreign microorganisms and substances that cause infection or disease.
  • Complex regulatory mechanisms ensure that the immune response is targeted against the intruding substance or organism and not against the host. In some cases, these control mechanisms are unregulated and autoimmune responses can develop. A consequence of the uncontrolled inflammatory response is severe organ, cell, tissue or joint damage.
  • Typical drugs in this class include azathioprine, chlorambucil, cyclophosphamide, cyclosporin, or methotrexate.
  • Corticosteroids which reduce inflammation and suppress the immune response, may cause side effects when used in long term treatment.
  • Nonsteroidal anti-inflammatory drugs NSAIDs
  • Alternative treatments include agents that activate or block cytokine signaling.
  • Orally active compounds with immunomodulating properties, without compromising immune responses and with reduced side effects would significantly improve current treatments of uncontrolled inflammatory diseases.
  • Organ transplant recipients can experience some rejection even when they are taking immunosuppressive drugs. Rejection occurs most frequently in the first few weeks after transplantation, but rejection episodes can also happen months or even years after transplantation. Combinations of up to three or four medications are commonly used to give maximum protection against rejection while minimizing side effects. Current standard drugs used to treat the rejection of transplanted organs interfere with discrete intracellular pathways in the activation of T-type or B-type white blood cells.
  • drugs examples include cyclosporin, daclizumab, basiliximab, everolimus, or FK506, which interfere with cytokine release or signaling; azathioprine or leflunomide, which inhibit nucleotide synthesis; or 15-deoxyspergualin, an inhibitor of leukocyte differentiation.
  • the present invention provides novel compounds of Formula (I) that are agonists for the G protein-coupled receptor S1P 1 /EDG1 and have a powerful and long-lasting immunomodulating effect which is achieved by reducing the number of circulating and infiltrating T- and B-lymphocytes, without affecting their maturation, memory, or expansion.
  • the reduction of circulating T- / B-lymphocytes as a result of S1P 1 /EDG1 receptor agonism possibly in combination with the observed improvement of endothelial cell layer function associated with S1P 1 /EDG1 receptor activation, makes such compounds useful to treat uncontrolled inflammatory diseases and to improve vascular functionality.
  • the compounds of the present invention have a reduced activity on the S1P 3 receptor when compared to closest analogs disclosed in document D1. This becomes evident from the data listed in Table 1 and Table 2.
  • the compound of Example 1 of the present invention shows an EC 50 of 9950 nM for the S1P 3 receptor while its closests analog in document D1 (Example 57 of D1 ) shows an EC 50 value of 1540 nM.
  • the compound of Example 2 is clearly less potent on S1P 3 receptor when compared to its closest analog disclosed in document D1 (Example 101 of D1 ).
  • Example 5 of the present invention is significantly less potent on S1P 3 receptor when compared to its analog of document D1 (S-enantiomer of the racemate of Example 22 of D1 ), and the same is true for the compounds of Examples 7 and 8 and their corresponding analogs in document D1 (Example 204 and Example 233, respectively, of D1 ).
  • Example R 1 EC 50 [nM] S1P 1 S1P 3 1 ethyl 2.1 9950 2 n-propyl 0.7 1120 3 isopropyl 0.3 3940 4 n-butyl 1.8 700 5 isobutyl 0.2 757 6 isopentyl 5.1 2600 7 pent-3-yl 0.1 1340 8 cyclopentyl 0.1 736
  • Table 2 Closest Analog in D1 R 1 EC 50 [nM] S1P 1 S1P 3 to Example 1 (Example 57 of D1 ) ethyl 0.3 1540 to Example 2 (Example 101 of D1 ) n-propyl 0.4 310 to Example 5 (S-entiomer of Example 22 of D1) isobutyl 0.1 33 to Example 7 (Example 204 of D1 ) pent-3-yl 0.2 44 to Example 8 (Example 233 of D1 ) cyclopentyl 0.2 47
  • the compounds of the present invention can be utilized alone or in combination with standard drugs inhibiting T-cell activation, to provide a new immunomodulating therapy with a reduced propensity for infections when compared to standard immunosuppressive therapy. Furthermore, the compounds of the present invention can be used in combination with reduced dosages of traditional immunosuppressant therapies, to provide on the one hand effective immunomodulating activity, while on the other hand reducing end organ damage associated with higher doses of standard immunosuppressive drugs.
  • S1P 1 /EDG1 receptor activation provides additional benefits of compounds to improve vascular function.
  • the nucleotide sequence and the amino acid sequence for the human S1P 1 /EDG1 and S1P 3 /EDG3 receptors are known in the art and are published in e.g.: Hla, T., and Maciag, T., J. Biol Chem. 265 (1990), 9308-9313 ; WO 91/15583 published 17 October 1991 ; WO 99/46277 published 16 September 1999 ; Yamaguchi F., Tokuda M., Hatase O., Brenner S., Biochem. Biophys. Res. Commun.
  • C 2-5 -alkyl means saturated, branched or straight chain alkyl groups with two to five carbon atoms.
  • the compounds of Formula (I) may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms.
  • the compounds of Formula (I) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.
  • salts refers to salts that retain the desired biological activity of the subject compound and exhibit minimal undesired toxicological effects. Such salts include inorganic or organic acid and/or base addition salts depending on the presence of basic and/or acidic groups in the subject compound.
  • Such salts include inorganic or organic acid and/or base addition salts depending on the presence of basic and/or acidic groups in the subject compound.
  • the present invention also includes isotopically labelled, especially 2 H (deuterium) labelled compounds of Formula (I), which compounds are identical to the compounds of Formula (I) except that one or more atoms have each been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
  • Isotopically labelled, especially 2 H (deuterium) labelled compounds of Formula (I) and salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope 2 H (deuterium) may lead to greater metabolic stability, resulting e.g. in increased in vivo half-life or reduced dosage requirements, or may lead to reduced inhibition of cytochrome P450 enzymes, resulting e.g. in an improved safety profile.
  • the compounds of Formula (I) are not isotopically labelled, or they are labelled only with one or more deuterium atoms. In a sub-embodiment, the compounds of Formula (I) are not isotopically labelled at all. Isotopically labelled compounds of Formula (I) may be prepared in analogy to the methods described hereinafter, but using the appropriate isotopic variation of suitable reagents or starting materials.
  • pyridine compounds according to Formula (I) are selected from:
  • the compounds of Formula (I) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral (such as especially oral) or parenteral (including topical application or inhalation) administration, and are suitable for decreasing the number of circulating lymphocytes and for the prevention and/or treatment of diseases or disorders associated with an activated immune system.
  • compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition (2005 ), Part 5, " Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins ]) by bringing the described compounds of Formula (I) or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, pharmaceutically acceptable solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
  • compositions comprising a compound of Formula (I) are useful for the prevention and/or treatment of diseases or disorders associated with an activated immune system.
  • Such diseases or disorders associated with an activated immune system and to be prevented/treated with the compounds of Formula (I) are for example selected from the group consisting of rejection of transplanted organs, tissue or cells; graft-versus-host diseases brought about by transplantation; autoimmune syndromes including rheumatoid arthritis; systemic lupus erythematosus; antiphospholipid syndrome; Hashimoto's thyroiditis; lymphocytic thyroiditis; multiple sclerosis; myasthenia gravis; type I diabetes; uveitis; episcleritis; scleritis; Kawasaki's disease, uveo-retinitis; posterior uveitis; uveitis associated with Behcet's disease; uveomeningitis syndrome; allergic encephalomyelitis; chronic allograft vasculopathy; post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis; inflammatory and hyperproliferative skin
  • Preferred diseases or disorders to be treated and/or prevented with the compounds of Formula (I) are selected from the group consisting of rejection of transplanted organs such as kidney, liver, heart, lung, pancreas, cornea, and skin; graft-versus-host diseases brought about by stem cell transplantation; autoimmune syndromes including rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, psoriasis, psoriatic arthritis, thyroiditis such as Hashimoto's thyroiditis, and uveo-retinitis; atopic diseases such as rhinitis, conjunctivitis, and atopic dermatitis; asthma; type I diabetes; post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis; and solid cancers and tumor metastasis.
  • transplanted organs such as kidney, liver, heart, lung, pancreas, cornea, and skin
  • diseases or disorders to be treated and/or prevented with the compounds of Formula (I) are selected from the group consisting of rejection of transplanted organs selected from kidney, liver, heart and lung; graft-versus-host diseases brought about by stem cell transplantation; autoimmune syndromes selected from rheumatoid arthritis, multiple sclerosis, psoriasis, psoriatic arthritis, Crohn's disease, and Hashimoto's thyroiditis; and atopic dermatitis.
  • diseases or disorders to be treated and/or prevented with the compounds of Formula (I) are selected from multiple sclerosis and psoriasis.
  • the present invention also relates to a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a compound of Formula (I).
  • compounds of the Formula (I) are also useful, in combination with one or several immunomodulating agents, for the prevention and/or treatment of the diseases and disorders mentioned herein.
  • said agents are selected from the group consisting of immunosuppressants, corticosteroids, NSAID's, cytotoxic drugs, adhesion molecule inhibitors, cytokines, cytokine inhibitors, cytokine receptor antagonists and recombinant cytokine receptors.
  • the present invention also relates to the use of a compound of Formula (I) for the preparation of a pharmaceutical composition, optionally for use in combination with one or several immunomodulating agents, for the prevention or treatment of the diseases and disorders mentioned herein.
  • the compounds of Formula (I) can be manufactured by the methods given below, by the methods given in the Examples or by analogous methods. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by a person skilled in the art by routine optimisation procedures.
  • Compounds of Formula (I) are prepared by reacting a compound of Structure 1 in a solvent such as toluene, pyridine, DMF, THF, dioxane, DME, etc. at rt or elevated temperatures in the presence or absence of auxiliaries such as acids (e.g. TFA, acetic acid, HCl, etc.), bases (e.g. NaH, NaOAc, Na 2 CO 3 , K 2 CO 3 , NEt 3 , etc.), tetraalkylammonium salts, or water removing agents (e.g.
  • a solvent such as toluene, pyridine, DMF, THF, dioxane, DME, etc.
  • auxiliaries such as acids (e.g. TFA, acetic acid, HCl, etc.), bases (e.g. NaH, NaOAc, Na 2 CO 3 , K 2 CO 3 , NEt 3 , etc.), tetraalkylammonium
  • Compounds of Structure 1 may be prepared by reacting a compound of Structure 2 with a compound of Structure 3 in a solvent such as DMF, THF, DCM, etc. in the presence of one or more coupling agents such as TBTU, DCC, EDC, HBTU, CDI, etc. and in the presence or absence of a base such as NEt 3 , DIPEA, NaH, K 2 CO 3 , etc. (Lit.: e.g. A. Hamze, J.-F. Hernandez, P. Fulcrand, J. Martinez, J. Org. Chem. 68 (2003), 7316-7321 ; and the literature cited above).
  • a solvent such as DMF, THF, DCM, etc.
  • one or more coupling agents such as TBTU, DCC, EDC, HBTU, CDI, etc.
  • a base such as NEt 3 , DIPEA, NaH, K 2 CO 3 , etc.
  • Compounds of Structure 3 may be prepared by reacting a compound of Structure 4, with hydroxylamine or one of its salts in a solvent such as MeOH, EtOH, pyridine, etc. in the presence or absence of a base such as Na 2 CO 3 , K 2 CO 3 , potassium tert.butylate, NEt 3 , etc. (Lit.: e.g. E. Meyer, A. C. Joussef, H. Gallardo, Synthesis 2003, 899-905 , WO 2004/035538 (Merck & Co., Inc., USA)).
  • a solvent such as MeOH, EtOH, pyridine, etc.
  • a base such as Na 2 CO 3 , K 2 CO 3 , potassium tert.butylate, NEt 3 , etc.
  • Compounds of Structure 2 may be prepared by reacting 2-chloro-isonicotinic acid or a suitable ester derivative thereof (Structure 5, wherein R represents e.g. methyl, ethyl, isopropyl, etc.) with dialkyl-Zn, an alkyl-Zn or cycloalkyl-Zn halogen reagent under Negishi conditions (Lit.: e.g. H. Matsushita, E. Negishi, J. Org. Chem.
  • the stereoisomers can be separated using methods known to one skilled in the art: e.g. by formation and separation of diastereomeric salts or by HPLC over a chiral stationary phase such as a Daicel ChiralPak AD-H (5 ⁇ m) column, a Daicel ChiralCel OD-H (5 ⁇ m) column, a Daicel ChiralCel OD (10 ⁇ m) column, a Daicel ChiralPak IA (5 ⁇ m) column, a Daicel ChiralPak IB (5 ⁇ m) column, a Daicel ChiralPak IC (5 ⁇ m) column, or a (R,R)-Whelk-01 (5 ⁇ m) column.
  • Typical conditions of chiral HPLC are an isocratic mixture of eluent A (EtOH, in presence or absence of a base like NEt 3 and/or diethylamine or of an acid like TFA) and eluent B (heptane).
  • eluent A EtOH, in presence or absence of a base like NEt 3 and/or diethylamine or of an acid like TFA
  • eluent B heptane
  • GTP ⁇ S binding assays are performed in 96 well microtiter plates (Nunc, 442587) in a final volume of 200 ⁇ l, using membrane preparations of CHO cells expressing recombinant human S1P 1 receptor or human S1P 3 receptor. Assay conditions are 20 mM HEPES (Fluka, 54461), 100 mM NaCl (Fluka, 71378), 5 mM MgCl 2 (Fluka, 63064), 0.1% BSA (Calbiochem, 126609), 1 ⁇ M GDP (Sigma, G-7127), 2.5% DMSO (Fluka, 41644), 50 pM 35 S-GTP ⁇ S (Amersham Biosciences, SJ1320).
  • Assay conditions are 20 mM HEPES (Fluka, 54461), 100 mM NaCl (Fluka, 71378), 5 mM MgCl 2 (Fluka, 63064), 0.1% BSA (
  • Test compounds are dissolved and diluted in 100% DMSO and pre-incubated at room temperature for 30 min in 150 ⁇ l of the above assay buffer, in the absence of 35 S-GTP ⁇ S. After addition of 50 ⁇ l of 35 S-GTP ⁇ S, the assay is incubated for 1 h at rt.
  • the assay is terminated by transfer of the reaction mixture to a Multiscreen plate (Millipore, MAHFC1H60) using a cell harvester from Packard Biosciences, and the plates are washed with ice-cold 10 mM Na 2 HPO 4 /NaH 2 PO 4 (70%/30%), dried, sealed at the bottom and, after addition of 25 ⁇ l MicroScint20 (Packard Biosciences, order# 6013621), sealed on the top. Membrane-bound 35 S-GTP ⁇ S is measured with a TopCount from Packard Biosciences.
  • EC 50 is the concentration of agonist inducing 50 % of the maximal specific 35 S-GTP ⁇ S binding. Specific binding is determined by subtracting non-specific binding from maximal binding. Maximal binding is the amount of cpm bound to the Multiscreen plate in the presence of 10 ⁇ M of S1 P. Non-specific binding is the amount of binding in the absence of an agonist in the assay.
  • Agonistic activities (EC 50 values) of all exemplified compounds have been measured and are in the range of 0.1 to 5.1 nM with an average of 1.3 nM on S1P 1 receptor.
  • EC 50 values on S1P 3 receptor are in the range of 700 and 9950 with an average of 2641 nM.
  • Agonistic activities are displayed in Table 3.
  • the efficacy of the compounds of Formula (I) is assessed by measuring the circulating lymphocytes after oral administration of 3 to 30 mg/kg of a compound of Formula (I) to normotensive male Wistar rats.
  • the animals are housed in climate-controlled conditions with a 12 h-light/dark cycle, and have free access to normal rat chow and drinking water. Blood is collected before and 3, 6 and 24 h after drug administration. Full blood is subjected to hematology using Advia Hematology system (Bayer Diagnostics, Zurich, Switzerland).
  • Table 4 shows the effect on lymphocyte counts 6 h after oral administration of 10 mg/kg of a compound of the present invention to normotensive male Wistar rats as compared to a group of animals treated with vehicle only. Lymphocyte counts 6 h after oral administration have been measured for 2 out of 8 exemplified compounds and are in the range of -71% to -73% with an average of -72%. Table 4: Compound of Example Lymphocyte counts 7 -71% 8 -73%

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
EP14715427.2A 2013-03-15 2014-03-14 Pyridin-4-yl derivatives Active EP2970236B1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
NO14715427A NO2970236T3 (es) 2013-03-15 2014-03-14
SI201430428T SI2970236T1 (sl) 2013-03-15 2014-03-14 Derivati piridil-4-ila
PL14715427T PL2970236T3 (pl) 2013-03-15 2014-03-14 Pochodne pirydyn-4-ylowe
EP14715427.2A EP2970236B1 (en) 2013-03-15 2014-03-14 Pyridin-4-yl derivatives
HRP20171763TT HRP20171763T1 (hr) 2013-03-15 2017-11-15 Derivati piridin-4-ila
CY20171101239T CY1119619T1 (el) 2013-03-15 2017-11-24 Παραγωγα πυριδιν-4-υλιου

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13159482 2013-03-15
EP14715427.2A EP2970236B1 (en) 2013-03-15 2014-03-14 Pyridin-4-yl derivatives
PCT/IB2014/059794 WO2014141171A1 (en) 2013-03-15 2014-03-14 Pyridin-4-yl derivatives

Publications (2)

Publication Number Publication Date
EP2970236A1 EP2970236A1 (en) 2016-01-20
EP2970236B1 true EP2970236B1 (en) 2017-08-30

Family

ID=47877933

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14715427.2A Active EP2970236B1 (en) 2013-03-15 2014-03-14 Pyridin-4-yl derivatives

Country Status (34)

Country Link
US (1) US9617250B2 (es)
EP (1) EP2970236B1 (es)
JP (1) JP6387361B2 (es)
KR (1) KR102212975B1 (es)
CN (1) CN105189487B (es)
AR (1) AR095523A1 (es)
AU (1) AU2014229217B2 (es)
BR (1) BR112015023161B1 (es)
CA (1) CA2900910C (es)
CL (1) CL2015002620A1 (es)
CY (1) CY1119619T1 (es)
DK (1) DK2970236T3 (es)
EA (1) EA029309B1 (es)
ES (1) ES2649475T3 (es)
HK (1) HK1220454A1 (es)
HR (1) HRP20171763T1 (es)
HU (1) HUE035154T2 (es)
IL (1) IL241363B (es)
LT (1) LT2970236T (es)
MA (1) MA38482B1 (es)
MX (1) MX363545B (es)
MY (1) MY173573A (es)
NO (1) NO2970236T3 (es)
NZ (1) NZ713080A (es)
PH (1) PH12015502118B1 (es)
PL (1) PL2970236T3 (es)
PT (1) PT2970236T (es)
SA (1) SA515361104B1 (es)
SG (1) SG11201507227UA (es)
SI (1) SI2970236T1 (es)
TW (1) TWI623534B (es)
UA (1) UA115357C2 (es)
WO (1) WO2014141171A1 (es)
ZA (1) ZA201507657B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
BR112015016793B1 (pt) 2013-01-15 2021-12-28 Incyte Holdings Corporation Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
CN114573574A (zh) 2015-05-20 2022-06-03 爱杜西亚药品有限公司 一种化合物的结晶形式
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
WO2017004610A1 (en) * 2015-07-02 2017-01-05 Exelixis, Inc. Tercyclic s1p3-sparing, s1p1 receptor agonists
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015583A1 (en) 1990-04-05 1991-10-17 The American National Red Cross A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
WO1999046277A1 (en) 1998-03-09 1999-09-16 Smithkline Beecham Corporation HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE
WO2004035538A1 (en) 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
AU2007292993B2 (en) * 2006-09-07 2013-01-24 Idorsia Pharmaceuticals Ltd Pyridin-4-yl derivatives as immunomodulating agents
AU2007292992B2 (en) 2006-09-08 2013-01-10 Actelion Pharmaceuticals Ltd Pyridin-3-yl derivatives as immunomodulating agents
AU2007298593A1 (en) 2006-09-21 2008-03-27 Actelion Pharmaceuticals Ltd Phenyl derivatives and their use as immunomodulators
MX2009009597A (es) 2007-03-16 2009-09-16 Actelion Pharmaceuticals Ltd Derivados de amino-piridina como agonistas del receptor s1p1/edg1.
EP2195311B1 (en) 2007-08-17 2011-03-23 Actelion Pharmaceuticals Ltd. Pyridine derivatives as s1p1/edg1 receptor modulators
US8202865B2 (en) 2007-10-04 2012-06-19 Merck Serono Sa Oxadiazole derivatives
BRPI0818804A2 (pt) 2007-11-01 2015-04-22 Actelion Pharmaceuticals Ltd Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
WO2009109907A1 (en) 2008-03-06 2009-09-11 Actelion Pharmaceuticals Ltd Novel pyrimidine-pyridine derivatives
CA2714665A1 (en) 2008-03-06 2009-09-11 Actelion Pharmaceuticals Ltd Pyridine compounds
AU2009220861B2 (en) * 2008-03-07 2014-05-29 Idorsia Pharmaceuticals Ltd Pyridin-2-YL derivatives as immunomodulating agents
ES2389469T3 (es) 2008-03-07 2012-10-26 Actelion Pharmaceuticals Ltd. Derivados novedosos de aminometilbeceno
HUE025984T2 (hu) * 2008-05-14 2016-05-30 Scripps Research Inst Szfingozin foszfát receptor új modulátorai
JP5753104B2 (ja) 2009-03-03 2015-07-22 メルク セローノ ソシエテ アノニム Ｓ１ｐ１レセプターアゴニストとして有用なオキサゾールピリジン誘導体
PT2454255E (pt) 2009-07-16 2014-01-14 Actelion Pharmaceuticals Ltd Derivados de piridin-4-il como agonistas de s1/p1/edg1
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
US9133179B2 (en) 2011-01-19 2015-09-15 Actelion Pharmaceuticals Ltd. 2-methoxy-pyridin-4-yl-derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
IL241363B (en) 2018-11-29
SA515361104B1 (ar) 2016-06-28
HUE035154T2 (en) 2018-05-02
HRP20171763T1 (hr) 2017-12-29
CA2900910A1 (en) 2014-09-18
MX2015012293A (es) 2015-12-16
EA201500931A1 (ru) 2016-03-31
MY173573A (en) 2020-02-04
UA115357C2 (uk) 2017-10-25
NZ713080A (en) 2020-06-26
PH12015502118A1 (en) 2016-01-25
LT2970236T (lt) 2017-11-10
EP2970236A1 (en) 2016-01-20
BR112015023161A2 (pt) 2017-07-18
AU2014229217B2 (en) 2017-12-14
US9617250B2 (en) 2017-04-11
PH12015502118B1 (en) 2016-01-25
US20160031866A1 (en) 2016-02-04
TW201443044A (zh) 2014-11-16
HK1220454A1 (zh) 2017-05-05
MA38482B1 (fr) 2018-11-30
IL241363A0 (en) 2015-11-30
JP2016512227A (ja) 2016-04-25
AR095523A1 (es) 2015-10-21
JP6387361B2 (ja) 2018-09-05
MX363545B (es) 2019-03-27
KR102212975B1 (ko) 2021-02-05
CL2015002620A1 (es) 2016-03-18
EA029309B1 (ru) 2018-03-30
ES2649475T3 (es) 2018-01-12
DK2970236T3 (en) 2017-10-16
SG11201507227UA (en) 2015-10-29
PL2970236T3 (pl) 2018-01-31
BR112015023161B1 (pt) 2022-11-16
WO2014141171A1 (en) 2014-09-18
TWI623534B (zh) 2018-05-11
PT2970236T (pt) 2017-11-30
CA2900910C (en) 2021-03-30
BR112015023161A8 (pt) 2021-06-22
CN105189487B (zh) 2017-12-26
KR20150128947A (ko) 2015-11-18
CN105189487A (zh) 2015-12-23
SI2970236T1 (sl) 2017-11-30
NO2970236T3 (es) 2018-01-27
AU2014229217A1 (en) 2015-11-05
CY1119619T1 (el) 2018-04-04
ZA201507657B (en) 2022-08-31
MA38482A1 (fr) 2017-12-29

Similar Documents

Publication Publication Date Title
EP2970236B1 (en) Pyridin-4-yl derivatives
EP2454255B1 (en) Pyridin-4-yl derivatives as s1p1/edg1 agonists
EP2069318B1 (en) Phenyl derivatives and their use as immunomodulators
EP2069335B1 (en) Pyridin-3-yl derivatives as immunomodulating agents
EP1979345B1 (en) Novel pyridine derivatives
EP2252609B1 (en) Pyridin-2-yl derivatives as immunomodulating agents
WO2005123677A1 (en) 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
WO2009109907A1 (en) Novel pyrimidine-pyridine derivatives
EP2665720B1 (en) 2-methoxy-pyridin-4-yl derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151015

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20161108

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20170324

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1220454

Country of ref document: HK

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IDORSIA PHARMACEUTICALS LTD

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 923418

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014013799

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20171011

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20171763

Country of ref document: HR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2970236

Country of ref document: PT

Date of ref document: 20171130

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20171123

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20171763

Country of ref document: HR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2649475

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180112

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E014606

Country of ref document: EE

Effective date: 20171113

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20170830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170830

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 5

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E035154

Country of ref document: HU

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20170403107

Country of ref document: GR

Effective date: 20180420

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170830

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014013799

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1220454

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20180531

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20171763

Country of ref document: HR

Payment date: 20190301

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180314

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20171763

Country of ref document: HR

Payment date: 20200303

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170830

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20171763

Country of ref document: HR

Payment date: 20210308

Year of fee payment: 8

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 923418

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170830

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20171763

Country of ref document: HR

Payment date: 20220309

Year of fee payment: 9

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20171763

Country of ref document: HR

Payment date: 20230309

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: RO

Payment date: 20230307

Year of fee payment: 10

Ref country code: NO

Payment date: 20230324

Year of fee payment: 10

Ref country code: MC

Payment date: 20230323

Year of fee payment: 10

Ref country code: LU

Payment date: 20230324

Year of fee payment: 10

Ref country code: LT

Payment date: 20230221

Year of fee payment: 10

Ref country code: IE

Payment date: 20230323

Year of fee payment: 10

Ref country code: FR

Payment date: 20230324

Year of fee payment: 10

Ref country code: FI

Payment date: 20230321

Year of fee payment: 10

Ref country code: DK

Payment date: 20230323

Year of fee payment: 10

Ref country code: CZ

Payment date: 20230306

Year of fee payment: 10

Ref country code: BG

Payment date: 20230322

Year of fee payment: 10

Ref country code: AT

Payment date: 20230322

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230313

Year of fee payment: 10

Ref country code: SK

Payment date: 20230307

Year of fee payment: 10

Ref country code: SI

Payment date: 20230302

Year of fee payment: 10

Ref country code: SE

Payment date: 20230314

Year of fee payment: 10

Ref country code: PT

Payment date: 20230302

Year of fee payment: 10

Ref country code: PL

Payment date: 20230303

Year of fee payment: 10

Ref country code: LV

Payment date: 20230320

Year of fee payment: 10

Ref country code: IS

Payment date: 20230317

Year of fee payment: 10

Ref country code: HU

Payment date: 20230323

Year of fee payment: 10

Ref country code: HR

Payment date: 20230309

Year of fee payment: 10

Ref country code: GR

Payment date: 20230327

Year of fee payment: 10

Ref country code: GB

Payment date: 20230322

Year of fee payment: 10

Ref country code: EE

Payment date: 20230315

Year of fee payment: 10

Ref country code: DE

Payment date: 20230321

Year of fee payment: 10

Ref country code: CY

Payment date: 20230217

Year of fee payment: 10

Ref country code: BE

Payment date: 20230321

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230321

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230328

Year of fee payment: 10

Ref country code: ES

Payment date: 20230529

Year of fee payment: 10

Ref country code: CH

Payment date: 20230401

Year of fee payment: 10

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602014013799

Country of ref document: DE

Representative=s name: KRAUS & LEDERER PARTGMBB, DE